General
Preferred name
DARUNAVIR
Synonyms
UIC 94017 ()
Darunavir Ethanolate ()
TMC114 ()
DARUNAVIR ETHANOLATE ()
Symtuza-darunavir ()
Darunavir (Ethanolate) ()
TMC114 (Ethanolate) ()
UIC-94017 ()
TMC-114, UIC 94017 ()
TMC114,DRV ()
Darunavir ethanolate component of symtuza darunavir ()
Tmc114 ethanolate ()
Rezolsta ()
Prezista ()
Darunavir ethanolate component of prezcobix ()
Darunavir monoethanolate ()
Darunavir (as ethanolate) ()
Darunavir krka d.d. ()
Darunavir viatris (previously darunavir mylan) ()
TMC-41629 ()
TMC-114 ()
UIC-940T ()
TMC 114 ()
Darunavir component of symtuza ()
Darunavir component of prezcobix ()
Darunavir krka ()
(-)-darunavir ()
Darunavir-d9 ()
P&D ID
PD009930
CAS
206361-99-1
635728-49-3
635728-39-1
618109-00-5
1133378-37-6
Tags
available
drug
Approved by
FDA
EMA
PMDA
First approval
2006
Drug indication
Human immunodeficiency virus infection
HIV infection
Hepatitis C virus infection
Human immunodeficiency virus-1 infection
Drug Status
investigational
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Darunavir ethanolate (TMC114 Ethanolate) is a potent HIV protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a Ki of 1 nM for wild type HIV-1 protease.
PRICE 51
DESCRIPTION Darunavir is a second-generation human immunodeficiency virus 1 (HIV-1) protease inhibitor (PI) . (GtoPdb)
DESCPRITION An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.
DESCRIPTION Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 ¦ÌM; IC90 = 0.009 ¦ÌM) with minimal cytotoxicity[1][2].
PRICE 49
DESCRIPTION Darunavir Ethanolate (UIC 94017) is an HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS. (TargetMol Bioactive Compound Library)
DESCRIPTION Darunavir is a HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection in patients with history of prior antiretroviral therapies. (Enamine Bioactive Compounds)
DESCRIPTION Potent inhibitor of TGF-betaRI (Tocris Bioactive Compound Library)
DESCRIPTION Darunavir (TMC114) is an HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
7
Compound Sets
26
AdooQ Bioactive Compound Library
A11853
A20829
Axon Medchem Screening Library
3137
Cayman Chemical Bioactives
31083
15866
25220
ChEMBL Approved Drugs
CHEMBL1201127
CHEMBL1323
ChEMBL Drugs
CHEMBL1201127
CHEMBL1323
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01264
DrugBank Approved Drugs
DB01264
DrugCentral
4143
DrugCentral Approved Drugs
4143
DrugMAP
DMN3GCH
DrugMAP Approved Drugs
DMN3GCH
Enamine Bioactive Compounds
EBC-27304
EU-OPENSCREEN Bioactive Compound Library
EOS100789
Guide to Pharmacology
11243
MedChem Express Bioactive Compound Library
HY-17041
HY-17040
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
YO603Y8113
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Darunavir-Ethanolate(Prezista)
darunavir
TargetMol Bioactive Compound Library
T3335
T2324
Tocris Bioactive Compound Library
6710
VGSC-DB
NA0117
NA0118
External IDs
353
Properties
(calculated by RDKit )
Molecular Weight
547.24
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
11
Ring Count
4
Aromatic Ring Count
2
cLogP
2.38
TPSA
140.42
Fraction CSP3
0.52
Chiral centers
5.0
Largest ring
6.0
QED
0.36
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
HIV Protease
WT HIV-1 protease
CYP3A4
HIV protease inhibitor
COVID-19,HIV Protease
Primary Target
Other Proteases
MOA
Inhibitor
HIV Protease inhibitor
Indication
human immunodeficiency virus (HIV-1)
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antiviral
Therapeutic Class
Antiviral Agents
VGSC Target
Nav1.5
Pathway
Anti-infection
Metabolic Enzyme/Protease
Microbiology/virology
Proteases/Proteasome
Source data